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Abstract 
Introduction: Infants <2 months are at greatest risk for morbidity/mortality from pertussis.  Tdap 
vaccines given in late pregnancy or postpartum can protect infants from pertussis.  Pregnancy 
increases risks for maternal and perinatal complications.  Influenza vaccine (FLUV) given in 
pregnancy can protect women and newborns.  
Objectives: To determine Tdap and FLUV rates in pregnant and postpartum patients and identify 
factors associated with vaccination. 
Methods: Miami Valley Hospital delivery records from 01/2009-12/2011 were retrospectively 
reviewed.  Data reviewed included age, insurance, race/ethnicity, and county of residence.  
Descriptive statistics analyzed prevalence of immunization, timing, and demographics.  Chi-
square and odds ratios detected differences between characteristics. 
Main Findings: A total of 13704 charts were reviewed.  Tdap was administered to 42%, with 
93% vaccinated within 10 days after birth.  Tdap uptake was significantly greater among 
younger mothers (49%, p=0.023), those with government insurance (48%, p<0.0001), and in 
black mothers (46.8%, p=0.023).  FLUV was given to 18% during the study period with 78% 
vaccinated between the third trimester and the 6-week postpartum visit.  FLUV vaccination was 
significantly greater among mothers living within Montgomery County (19.4%, p<0.0001) and 
among black (17.63%, p=0.008) mothers.  Vaccination rates for both Tdap and FLUV increased 
over the study period, from 30% to 53% and 11% to 23%, respectively.   
Conclusions: Despite current recommendations, only a minority received vaccinations during 
pregnancy or postpartum. Vaccination rates increased over time and with certain demographics. 
Improved strategies may increase FLUV and Tdap administration in this population.  
Keywords: pertussis, influenza, vaccination, maternal  
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Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccination and Influenza 
Vaccination of Pregnant and Postpartum Women 
Infectious diseases continue to cause significant morbidity and mortality in the infant 
population despite advances in prevention.  Two such airborne diseases, influenza and pertussis, 
can be prevented in many infants; these are the only two diseases in which immunization during 
pregnancy is recommended to reduce disease in infants (Fortner, Kuller, Rhee, & Edwards, 
2012).  Most pertussis-related hospitalizations and deaths occur in infants <2 months (Bisgard et 
al., 2004; Castagnini et al., 2012; CDC, 2010a; Gerbie & Tan, 2009; Wendelboe, Hudgens, 
Poole, & Van Rie, 2007a; Wendelboe et al., 2007b).  Tetanus toxoid, reduced diphtheria toxoid 
and acellular pertussis (Tdap) vaccines administered in late pregnancy or in the early postpartum 
period have been shown to protect infants from pertussis (Bisgard et al., 2004; Castagnini et al., 
2012; CDC, 2008; CDC, 2010b; Gall, Myers, & Pinchichero, 2011; Gerbie & Tan, 2009; 
Murphy et al., 2008).  
Influenza is a respiratory disease caused by the influenza virus, which similarly leads to 
infection in all age groups, with extensive morbidity and mortality in the infant population, 
elderly population, and pregnant population.  Pregnancy increases the risk for maternal influenza 
complications (CDC, 2011b; CDC, 2011c) and influenza during pregnancy may result in adverse 
perinatal or delivery complications (Bloom-Feshbach et al., 2011; Steinhoff et al., 2012).  As 
with pertussis, the influenza vaccine (FLUV) given in pregnancy can protect women and 
newborns (Benowitz, Esposito, Gracey, Shapiro, & Vazquez, 2010; Bloom-Feshbach et al., 
2011; Louie, Acosta, Jamieson, Honein, & California Pandemic [H1N1] Working Group, 2010; 
Murphy et al., 2008; Poehling et al., 2011; Steinhoff et al., 2012).  
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The Advisory Committee on Immunization Practices (ACIP) recommends that all 
postpartum women who were not previously vaccinated with Tdap receive the vaccine prior to 
hospital discharge (Murphy et al., 2008).  In July 2011, the ACIP recommended that pregnant 
women at >20 weeks gestation also receive the Tdap vaccine.  Finally, the ACIP recommends 
that all pregnant women receive the influenza vaccine (CDC, 2012b).  
Purpose Statement 
The purpose of this cross-sectional analysis is to examine the proportion of pregnant and 
postpartum women who receive the pertussis and influenza vaccines as recommended.  A second 
objective of this study is to determine barriers to universal Tdap and FLUV immunization in 
unvaccinated women.   
Research Questions 
1) What percentage of women who gave birth at Miami Valley Hospital between January 1, 
2009 and December 31, 2011 is vaccinated against pertussis? 
2) What percentage of women who gave birth at Miami Valley Hospital between January 1, 
2009 and December 31, 2011 is vaccinated against influenza? 
3) What is the timing of vaccination for women who gave birth at Miami Valley Hospital 
between January 1, 2009 and December 31, 2011?   
4) What are the subpopulations not receiving these vaccinations of women who gave birth at 
Miami Valley Hospital between January 1, 2009 and December 31, 2011? 
5) What are the trends in vaccination of women who gave birth at Miami Valley Hospital 
between January 1, 2009 and December 31, 2011? 
6) What are the barriers to vaccination of women who gave birth at Miami Valley Hospital 
between January 1, 2009 and December 31, 2011? 
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7) What are successful means of improving vaccination rates of women who gave birth at 
Miami Valley Hospital between January 1, 2009 and December 31, 2011? 
Deliminations and Limitations 
This study was designed to look specifically at one hospital system in Dayton, Ohio.  
While there are other delivery centers in the area, Miami Valley Hospital is the largest and draws 
from all areas in the region, therefore it was assumed that this population would be most 
representative of the general population.  However, since only one center was chosen, a 
limitation of this data set is that an unknown number of women delivered at Miami Valley 
Hospital but received their pre- and/or post-natal care at outside facilities.  Those women may 
have been vaccinated at other medical centers, and their vaccination records may not be available 
within the Miami Valley Hospital records.  Therefore, the data set is likely incomplete.   
Review of Literature 
Disease Course, Pertussis 
Pertussis is one of the few vaccine-preventable diseases that still cause significant 
morbidity and mortality in the United States.  Despite preventative recommendations for 
vaccination, deaths from pertussis continue to occur, with the majority of deaths (93%) from 
2005-2006 occurring in infants <12 months (CDC, 2008).  Most cases of pertussis are amenable 
to treatment, and recovery occurs in the majority.  Early infection with pertussis can be treated 
with antibiotics to prevent symptoms and spread of the disease, whereas treatment in later stages 
of the disease is only symptomatic (CDC, 2010b).  However, some infants have the propensity to 
develop malignant pertussis, in which the bacterial infection leads to severe acute respiratory 
failure.  In a 2010 retrospective cohort study conducted in France, ten infants between the ages of 
0.6 and 3 months were diagnosed with pertussis (Bouziri et al., 2010).  Nine out of ten infants 
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subsequently died due to complications from this infection.  Researchers retrospectively 
determined that due to their age and susceptibility to disease, these infants had malignant 
pertussis, and therefore were at increased risk for severe morbidity and mortality.  Pertussis leads 
to more extensive morbidity when compared to other respiratory infections in infants, with 
hospitalization in infants approaching 50% (de Greeff et al., 2010); it also leads to increased 
lengths of stays, increased need for oxygen, and longer duration of illness (Castagnini & Munoz, 
2010).  
Although the disease is usually present in the population at low levels, with only a few 
cases per 100,000 people, there are cyclic, epidemic-like increases in incidence due to the 
contagiousness of the bacteria.  These epidemics usually occur with a periodicity of 2-5 years 
(Broutin, Viboud, Grenfell, Miller, & Rohani, 2010).  Nationwide, there has been a recent 
increase in pertussis infections, most notably in California.  From January through June 2010, 
California experienced a 418% increase in pertussis infections when compared to 2009 
incidence.  As of August 2010, the state of California reported over 2,700 cases of pertussis for 
the calendar year, with eight infants dying from infection (CDC, 2010a).  In general, infants 
infected with pertussis have the most serious and life-threatening illnesses compared with other 
age groups.  With this national increase in pertussis infections, it is important to determine how 
infants are exposed to the illness in order to prevent illness and death.    
Disease Course, Influenza 
Influenza causes disease in all populations, with increased severity seen among infants 
and pregnant women.  Seasonal influenza occurs nearly every year and leads to increased 
hospitalizations, especially among infants <6 months and children with co-existing medical 
conditions (Yen, Louie, & Schechter, 2012).  It is estimated that 9-30 per 10,000 children are 
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hospitalized with influenza during any particular season (Dawood et al., 2010).  While the 
disease is usually self-limited, symptoms include headaches, myalgias, cough, malaise, and 
anorexia.  The disease can also lead to severe complications including pulmonary disease 
(pneumonia, asthma, croup, bronchitis), as well as heart, neurologic, and renal complications 
(Nicholson, 1992).  When pregnant women are infected with influenza, they have an increased 
risk of dying from influenza; in addition, their infants are more likely to be small for gestational 
age and preterm (CDC, 2011b).   
Epidemics are also seen with the influenza virus, typically from November to March 
(CDC, 2011c).  Seasonal epidemics occur yearly, though the timing and severity varies greatly 
from year-to-year.  Occasionally, pandemics occur when the virus’ genetic material changes 
drastically.  Two major pandemics are pertinent to this research study.  The first is the 1918 
“Spanish” influenza pandemic, which caused the death of 500,000 people in the United States 
alone and caused illness in even more (CDC, 1999).  During the 1918 influenza pandemic the 
birth rate was markedly reduced, likely related to an increase in first-trimester miscarriages 
(Bloom-Feshbach et al., 2011).  A second epidemic that occurred more recently was the 2009-
2010 H1N1 pandemic.  This greatly increased the morbidity and mortality among pregnant 
women (Louie et al., 2010) and infants (Yen et al., 2012).  During H1N1, infected infants 
manifested disease as gastrointestinal illness (36%), neurologic changes (10%), and pneumonia 
(34%); ten percent of infected children required admission to the Pediatric ICU (Blumental et al., 
2011).  Similar to pertussis, it is important to determine how infants are exposed in order to 
effectively prevent the disease.  
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Vaccines and Recommendations, Pertussis 
Two types of pertussis vaccines exist: whole cell (wP) and acellular (aP) vaccines.  The 
whole-cell vaccine, which is the older vaccine, is often heterogeneous in composition, with an 
efficacy ranging from 46% to 92% (Pertussis Vaccines, 2010).  This vaccine often composes the 
type given to infants within developing countries; however, the whole-cell type is not found in 
adolescent or adult pertussis vaccines.  The newer, more expensive acellular vaccine was 
developed in 1981 in Japan and is the type used in the United States.  Heterogeneity in the 
number of acellular components exists, but research has shown that vaccines with three or more 
components are the most effective: efficacy is about 89% for these vaccines when multiple doses 
are given (CDC, 2010b).  In addition, local and systemic reactogenicity is likely lower in aP 
vaccines compared to wP vaccines (Pertussis Vaccines, 2010).  
Natural infection with pertussis only leads to antibody development in 80-85% of those 
infected (Pertussis Vaccines, 2010).  Therefore, the protection conferred by such antibodies is 
not necessarily life-long.  Similarly, immunity wanes after vaccination.  Immunity lasts 
approximately 4-20 years after natural infection and approximately 4-12 years after 
immunization (Wendelboe, Van Rie, Salmaso, & Englund, 2005).  Therefore, multiple 
vaccinations with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine and later with a 
booster vaccine is recommended for all infants and adults, respectively, in order to prevent future 
infections and prevent the spread of disease to susceptible infants.  
The current US recommendations for prevention against pertussis include giving children 
four doses of the diphtheria, tetanus, and pertussis (DTaP) vaccine at two, four, six, and fifteen-
eighteen months of age.  A DTaP booster dose is recommended for children aged 4-6 years of 
age, and a Tdap booster is recommended at 11-12 years of age (CDC, 2012a).  Due to waning 
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 12 
immunity in the population, the ACIP has recommended that all adults, including postpartum 
women, substitute one Tdap vaccine for a Td booster (typically given every 10 years).  Finally, it 
is now recommended that pregnant women at 20 weeks gestation or greater receive the Tdap 
vaccine (CDC, 2012a).  Caregivers in close contact with any infant, including fathers, 
grandparents, siblings, and other caregivers, should receive the Tdap vaccine (Castagnini et al., 
2012).  Not only do these recommendations limit the spread of infection to infants, but also they 
have been found to be cost-effective compared to the cost of treating pertussis infections 
(Scuffham & McIntyre, 2004).  
Vaccines and Recommendations, Influenza 
Influenza vaccine efficacy varies among populations.  In healthy children, the efficacy is 
estimated to be 79% (Jefferson et al., 2005a), while for elderly living in long-term care facilities, 
the efficacy is closer to 45% (Jefferson et al., 2005b).  While vaccinating elderly is not as 
effective as vaccinating children, the vaccination of healthy children can provide protection to 
the elderly through herd immunity, with approximately a 60% reduction in influenza (Loeb et al., 
2010; Loeb, Russell, Fonseca, Webby, & Walter, 2011).  The US Department of Health and 
Human Services (2011) recommends that 80% healthy and 90% high-risk individuals receive the 
influenza vaccine each year; however, vaccination rates have rarely crossed 50% of the 
population.  In particular, rates of vaccination among pregnant women were only 15% prior to 
the H1N1 pandemic, although they jumped to approximately 50% during the pandemic (CDC, 
2011a).  It remains to be seen if these trends will continue in subsequent influenza seasons.  
Despite widespread availability of the vaccines, which are available at most pharmacies, 
supermarkets, physician offices and hospitals, influenza has been described as “the least 
controlled vaccine-preventable disease” (Glezen, 2004, p. 39).   
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The immunity conferred by natural infection with influenza has been estimated to be 
similar to vaccine immunity.  Like immunity from the vaccine, natural immunity does not 
provide protection from year-to-year because of the antigenic drift and shift of the virus.  
Therefore, yearly vaccination is recommended for all persons >6 months of age.  During the 
H1N1 pandemic (2009-2010 influenza season), it was recommended that all eligible persons 
receive both the seasonal vaccine and the H1N1 vaccine.  In addition, vaccination of pregnant 
women was recommended with both H1N1 and seasonal influenza vaccines.  When examining 
serum antibody levels, it was shown that vaccination with H1N1 and infection with H1N1 
conferred similar levels of immunity to infants via analysis of cord blood (Fisher et al., 2012), 
thereby protecting both the mother and fetus against the epidemic strain.   
The CDC recommends that the influenza vaccine, usually available from September 
through April, be given annually to all persons 6 months and older.  This includes pregnant 
women, or women who will be pregnant during flu season, as well as household contacts and 
caregivers of children less than five years old (CDC, 2012a).  Influenza infection among infants 
is greatly reduced if the mother is vaccinated (Benowitz et al., 2010; Poehling et al., 2011); the 
effectiveness of vaccinating the mother to protect the infant is estimated at 91-92% (Benowitz et 
al., 2010).  In addition, other infant respiratory illnesses are greatly reduced when the mother has 
been vaccinated (Steinhoff et al., 2012).  
Vaccination Strategies, Pertussis 
Even when DTaP vaccination is initiated at 6 weeks of age, infants are not fully immune 
until they have received multiple doses of the vaccine (CDC, 2010b).  Therefore, it is important 
to determine how infants are exposed to the illness in order to decrease their risk of disease.  A 
2010 study from the Netherlands showed that in cases where an infant is diagnosed with 
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pertussis, the source of infection often came from the household (de Greeff et al., 2010).  The 
source was discovered in 60% of cases, with a sibling being responsible for 41% of cases, a 
mother causing 38% of cases, and a father causing 17% of cases.  Another study found that 
siblings were the cause of infection in 36% of cases (with 3-4 year olds responsible for the 
majority), parents in 24% of cases, other family members in 21% of cases, and friends in 13% of 
cases (Jardine, Conaty, Lowbridge, Staff, & Vally, 2010).  In a 2004 study by Bisgard et al., 
mothers were deemed to be the source in 32% of infections, while another family member was 
responsible in 43% of cases.  More often than not, an infant who is exposed to pertussis infection 
receives the bacteria from a close family member.   
Immunizing family contacts against pertussis could greatly reduce the incidence of 
infection in young infants; this method of prevention is known as cocooning.  Cocooning is 
accomplished by protecting close contacts from pertussis infection via immunization with Tdap, 
thereby reducing disease transmission to infants and others.  A study of the Tdap vaccine during 
a pertussis outbreak on the US Virgin Islands found the vaccine to be 65.6% effective in 
preventing illness among adolescents (95% CI: -35.8% to 91.3%) and the relative risk of 
infection with pertussis in an unvaccinated adolescent compared to a vaccinated adolescent was 
2.9 (Wei et al., 2010).  A second efficacy study conducted in Australia found that the Tdap 
vaccine was 78% effective (95% CI: 60.7% to 87.6%) in preventing infection with pertussis 
among adolescents (Rank, Quinn, & McIntyre, 2009).  As estimated in mathematical modeling, 
cocooning through vaccination of mothers and fathers can decrease the disease incidence by 65-
70% (Van Rie & Hethcote, 2004).  However, a recent 2012 study showed that the number 
needed to vaccinate to prevent one infant death was estimated at 1 million persons (Skowronski 
et al., 2012).  A second study looking at implementation of cocooning in a high-risk population 
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described several barriers, including inaccurate recall of prior immunization (Healy, Rench, & 
Baker, 2011).  It remains to be seen whether the barriers to cocooning reduce cost-effectiveness; 
yet, the ACIP and other organizations continue to promote vaccination of close contacts as a 
method of protecting infants.    
In addition to cocooning, herd immunity can be used to prevent the spread of infection 
throughout the population.  This utilizes the principle and calculations of disease reproduction.  
When the number of individuals protected from infection (f) is greater than a calculated threshold 
(1-1/Ro, where Ro is the basic reproductive number), disease transmission will be eliminated.  It 
is not necessary to immunize 100% of the population to prevent an epidemic (Anderson & May, 
1990).  Based on this equation, the threshold estimated to eliminate pertussis is between 90-94% 
(Ward et al., 2005).  In order to maintain the disease at “non-epidemic” proportions, where 
secondary cases may occur without causing an epidemic, vaccination rates of approximately 
65% are required (Coudeville, Van Rie, & Andre, 2008).  A 2010 study conducted in Spain 
looked at this principle in three population groups: 6-9 years, 15-24 years, and 45-54 years 
(Plans, 2010).  By measuring the levels of antibody, and therefore immunity against pertussis, 
they discovered that only 42% of the population was immune.  Antibody prevalence was highest 
in the 6-9 years age group (the group most recently vaccinated).  Utilization of the Tdap vaccine 
in US adolescents and adults will likely increase f in these populations, but it is unclear if the 
vaccine can provide enough herd immunity to decrease or eliminate secondary cases of the 
disease. 
Another principle to protect infants is passive immunity, in which the fetus receives 
antibodies through the mother’s placenta during gestation (IgG antibodies), and later through 
colostrum (IgA antibodies); those IgG antibodies typically last several weeks, with IgA lasting as 
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long as breastfeeding occurs, thereby providing the infant with an immune system until he/she 
can develop his/her own (Baxter, 2007).  While antibody transfer does occur with pertussis 
antibodies (Gall et al., 2011; Quinello, Quintilio, Carneiro-Sampaio, & Palmeira, 2010), it is still 
unclear how effective these antibodies are at preventing disease in infants. 
Vaccination Strategies, Influenza 
Influenza contributes to approximately 36,000 deaths each year and over 200,000 
hospitalizations (US Department of Health and Human Services, 2011).  The rates of coverage 
with influenza vaccine have typically been low.  Among pregnant women, the rate was 
approximately 2.5% in 2003-2004 in one study.  With education and vaccine promotion among 
providers, the rate increased to 37.4% in 2008-2009 (the season prior to H1N1) (Mouzoon et al., 
2010).   
Influenza vaccines are not available for children until they have reached six months of 
age; so, direct vaccination is a method that cannot be currently employed to protect infants.  
However, similar to cocooning in pertussis, influenza vaccination of caregivers and close 
contacts may protect infants from the virus (Rimmelzwaan, Bodewes, & Osterhaus, 2011).  
While research on cocooning to prevent pertussis is rampant, there is little research on the 
benefits of cocooning to prevent influenza and its complications.  In the US, influenza 
vaccination rates are low, especially among caregivers of infants.  Rates range from 10-40% in 
healthy persons and 39-67% in high-risk individuals (CDC, 2011c).  
As described above, herd immunity can be protective for a population, even if 100% 
immunity is not achieved.  The threshold for herd immunity for influenza varies depending on 
the virus strain, seasonal attack rates, the vaccine effectiveness (which changes from year-to-
year) and the epidemic year.  It has been estimated to be between 0% and 100%, depending on 
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the variables described above (Plans-Rubio, 2012).  One study in Japan found that immunizing 
schoolchildren was an efficient method of achieving herd immunity.  By vaccinating just 420 
children in the community, one death from influenza could be prevented (Reichert et al., 2001).  
While a specific range for herd immunity is not available for preventing influenza, mathematical 
modeling by Plans-Rubio (2012) supports the Healthy People 2020 goals that 80% of pregnant 
women and 90% of high-risk persons should be vaccinated against influenza to prevent the 
spread of disease throughout the population (US Department of Health and Human Services, 
2011).  In addition, it has been shown that vaccinating children provide herd immunity to the 
elderly (Cohen, Chui, & Naumova, 2011) in a cost-effective manner (Loeb et al., 2010).  
The most studied method of disease prevention in infants is vaccinating pregnant mothers 
to confer passive immunity to infants.  IgG antibodies will cross the placenta, thereby providing 
protection for the infant (Kohler & Farr, 1966; Hobbs & Davis, 1967); as shown in a 2012 
randomized controlled trial, vaccinating pregnant women with influenza led to a 63% decrease in 
influenza infections among infants (Steinhoff et al., 2012).  A second study showed that 
vaccinating pregnant women was 91.5% effective in preventing hospitalizations among infants 
due to influenza infection (Benowitz et al., 2010). 
This study aims to quantify and describe (by demographic variables) the number of 
postpartum women who qualify for Tdap immunization but are not receiving Tdap immunization 
before discharge from the hospital.  This study will also quantify and describe the number of pregnant 
and postpartum women who do not receive the influenza vaccine.  A secondary objective will be to 
describe factors associated with failure to vaccinate.  The analysis will determine whether providers 
are following ACIP and hospital recommendations with respect to influenza and pertussis 
immunization in this population, as these may significantly affect the rate of disease in infants.  It may 
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 18 
also identify subpopulations at risk for not receiving the vaccines.  The findings will support changes 
in hospital immunization protocols and quality measures.  
Methods 
Subjects 
 The subjects included all women who gave birth at Miami Valley Hospital in Dayton, 
Ohio between January 2009 and December 2011.  No patients were excluded from the study.  No 
limitations were placed on study participants regarding age, county of residence, insurance 
status, race, or ethnicity.  
Measurement 
 The dependent variables in this study were: 1) vaccination with Tdap and, 2) vaccination 
with FLUV.  Timing of these vaccinations was recorded and compared to time of birth.  These 
dependent variables were measured as both continuous and categorical (Table 1).  The following 
independent variables were identified to be measured during analysis: age, county of residence, 
insurance status, race, and ethnicity (Table 1).   
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Table 1.  
Dependent and Independent Variables 
Dependent 
Variables 
Description Level of Measurement 
Tdap vaccine Receipt of vaccine and 
timing of vaccination 
Continuous; Categorical: yes/no; timing: 
pre-conception, during pregnancy, 
immediate postpartum, within 6-weeks 
postpartum 
FLUV vaccine Receipt of vaccine and 
timing of vaccination 
Continuous; Categorical: yes/no; timing: 
pre-conception, during pregnancy, 




Description Level of Measurement 
Age Mother's reported age at 
the time of infant's birth 




Mother's reported county 
of residence at the time 
of infant's birth 
Categorical: Montgomery,  Outside of 
Montgomery 
Insurance Status Mother's reported 
insurance status at the 
time of infant's birth 
Categorical: Commercial, Government,  
Other 
Race Mother's reported race at 
the time of infant's birth 
Categorical: White, Black, Other 
Ethnicity Mother's reported 
ethnicity at the time of 
infant's birth 
Categorical: Hispanic or Latino, Not 
Hispanic or Latino 
 
Data Collection and Descriptive Analysis 
This is a retrospective, descriptive analysis of the labor and delivery medical records at 
Miami Valley Hospital in Dayton, Ohio, which has been approved by the Miami Valley Hospital 
Institutional Review Board.  Data was collected by querying the Epic electronic medical record 
database for all postpartum patients; all charts from January 2009-December 2011 (36 months) 
were examined for influenza and pertussis vaccination status of new mothers.  Each medical 
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record was assigned a random code, and all data was stored under this random code in a 
password-protected Excel spreadsheet.  The patient medical record number linked to the random 
code was stored in a separate password-protected Excel spreadsheet, and that information will be 
destroyed at the end of the study.  No hard-copy data was obtained during this study.  A history 
of vaccination with Tdap or influenza by other caretakers was unavailable. 
Using a Microsoft Excel spreadsheet, all data was organized into categories such as “Date 
of Delivery,” “Vaccine Received,” and “Timing of Vaccine.”  Each delivery at Miami Valley 
Hospital was assessed for vaccination with Tdap at any time, and vaccination with influenza 
during that particular flu season.  The time of vaccination was recorded and compared to the time 
of birth.  The number of women receiving (a) Tdap prior, during, and within 6 weeks post-
delivery, and, (b) seasonal FLUV or H1N1 before or just after delivery at this hospital was 
collected.  Standard demographic data was also collected, including age, payer status 
(government, private, charity, etc.), county of residence, zip code, race, and ethnicity (See 
Appendix A).  Women were considered to have received the Tdap vaccine if it was administered 
up to 4 years prior to delivery, through the gestational period, and up to 6 weeks post-partum.  If 
a woman received the vaccine outside of that period, it was not counted as a positive history of 
vaccination.  Women were considered to have received the FLUV vaccine if it was given during 
pregnancy, or in the influenza season immediately preceding pregnancy if the woman conceived 
outside of flu season.  For example, if a woman conceived during May and was given a flu 
vaccine during March, that was considered a positive vaccination status.  A delivery was only 
counted once, regardless of whether the woman delivered one or multiple infants in that delivery.   
A separate Microsoft Excel spreadsheet was created to analyze Tdap data.  In this 
spreadsheet, a woman was only counted once in the entire study period, even if she had multiple 
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deliveries.  If a woman had delivered multiple times throughout the study period, the delivery 
positively associated with Tdap vaccination was included in the spreadsheet.  If a women had not 
received the Tdap vaccine with any pregnancy, or if a women had received the Tdap vaccine 
with two or more pregnancies, the delivery to be included in the study population was chosen at 
random.  Random selection entailed rotating through the three years in the study period: in the 
first instance of multiple deliveries, the delivery occurring at the earliest date was selected; in the 
second instance of multiple deliveries, the delivery occurring at the second earliest date was 
selected; and so on.  Descriptive statistics were employed to describe the population, determine 
the prevalence of vaccination, and determine the timing of vaccination.  The de-identified data 
was then transferred to SAS for statistical analysis.  
Statistical Analysis 
 Using SAS, Chi-Square was performed on both pertussis and influenza data to determine 
if the means among populations were significantly different.  Logistic regressions were 
performed on the same data sets.  P values of <0.05 were considered statistically significant for 
all analyses.  In addition, odds ratios were calculated to compare categories within the 
independent variables.   
Statement Regarding IRB Approval 
 Miami Valley Hospital’s Institutional Review Board reviewed and approved this study 
prior to initiating data collection or analysis.  IRB approval was obtained to ensure the protection 
of human subjects.  IRB renewal was obtained in 2011 so that the study could be continued for 
another year.   
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Results 
Patient Demographics 
Between January 1, 2009 and December 31, 2011, 13,704 deliveries occurred at Miami 
Valley Hospital.  Of these deliveries, 10.8% of women were less than 20 years of age; 78.4% of 
women were between the ages of 20 and 35; and 10.8% of women were aged 35 or greater.  
Sixty-two percent of women were residents of Montgomery County.  In regards to insurance 
status, 40.9% of women had private insurance, 54.8% of women had government insurance, and 
4.3% of women had other forms of payment (self-pay, charity care, etc.).  Of women delivering 
during the study period, 70% were white, 23% were black, and 7% were of another race.  
Ninety-six percent of women did not consider themselves Hispanic/Latino (Table 2).   
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Table 2. 
Demographic Characteristics of Study Participants (n=13,704) 
     n (%) 
Age   
  <20 1486 (10.8%) 
  20-34 10740 (78.4%) 
  35 or greater 1478 (10.8%) 
      
County of Residence   
  Montgomery 8457 (61.7%) 
  Outside of Montgomery 5247 (38.3%) 
      
Insurance Status   
  Commercial 5605 (40.9%) 
  Government 7506 (54.8%) 
  Self-Pay 99 (0.7%) 
  Charity 240 (1.8%) 
  Other 253 (1.8%) 
      
Race   
  White 9600 (70.1%) 
  Black 3091 (22.6%) 
  Other 1013 (7.4%) 
      
Ethnicity   
  Not Hispanic/Latino 13204 (96.4%) 
  Hispanic/Latino 477 (3.5%) 
 
Vaccination Rates, Pertussis 
During the 36-month study period, 5,304 women delivering babies, or 42% of subjects, 
received the Tdap vaccine at Miami Valley Hospital. Broken down by year, 30% of women in 
2009 received the vaccine; 42% of women in 2010 received the vaccine; and, 53% of women in 
2011 received the vaccine.  This 77% increase in immunizations over the study period was 
statistically significant (p<0.0001).  Forty-nine percent of women less than 20 years old received 
the vaccine, while 41.5% of women aged 20-34 and 36.2% of women 35 or greater received the 
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vaccine (p=0.0225).  Of women living in Montgomery County, 42.8% received the vaccine, 
while 40.1% of women living outside the county received the vaccine (p=0.1395).  Thirty-three 
percent of women with commercial insurance received the vaccine, while 48.2% of women with 
government insurance received the vaccine (p<0.0001).  In regards to race, 39.5% of white 
women received the vaccine and 46.8% of black women received the vaccine (p=0.0225).  Fifty-
one percent of Hispanic/Latino women and 41.4% of non-Hispanic/Latino women received the 
vaccine (p=0.4394; Table 3).    
Table 3.  
Analysis of Tdap Vaccination by Demographic Variables 
  Vaccinated n (%) Not vaccinated n (%) Chi-Square 
Year     <0.0001* 
2009 1301 (30.15%) 3014 (69.85%) <0.0001* 
2010 1798 (42.47%) 2436 (57.53%) <0.0001* 
2011 2205 (53.02%) 1954 (46.98) - 
Mother's Age   0.0225* 
<20  672 (49.12%) 696 (50.88%) - 
20-34 4120 (41.50%) 5807 (58.50%) 0.0458* 
>or=35 512 (36.23%) 901 (63.77%) 0.0234* 
County   0.1395 
Montgomery County 3336 (42.76%) 4466 (57.24%) - 
Outside Montgomery County 1968 (40.11%) 2938 (59.89%) - 
Insurance   <0.0001* 
Commercial 1718 (32.92%) 3500 (67.08%) <0.0001* 
Government 3338 (48.17%) 3592 (51.83%) - 
Self-Pay 34 (38.20%) 55 (61.80%) 0.0205* 
Charity 136 (59.65%) 92 (40.35%) 0.1676 
Other 78 (32.23%) 164 (67.77%) <0.0001* 
Race   0.0225* 
White 3530 (39.47%) 5413 (60.53%) 0.0374* 
Black 1325 (46.82%) 1505 (53.18%) - 
Other 438 (48.40%) 467 (51.60%) 0.3365 
Ethnicity   0.4394 
Not Hispanic/Latino 5072 (41.41%) 7175 (58.59%) - 
Hispanic/Latino 225 (51.37%) 213 (48.63%) - 
Note. * signifies that the value is significant as p<0.05. 
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The odds of receiving the vaccine were 1.55 times higher in 2011 than in 2010 (CI 1.42-
1.69) and 2.67 times higher in 2011 than 2009 (CI 1.42-1.69).  In addition, the odds of receiving 
the vaccine were 1.13 times higher for mothers less than 20 years old compared to mothers aged 
20-34 (CI 1.00-1.27), and 1.21 times higher than mothers 35 years old or greater (CI 1.03-1.42).  
Women with government insurance were 1.85 times more likely to be vaccinated than those with 
commercial insurance (CI 1.70-2.01); 1.69 times more likely than women self-paying (CI 1.08-
2.63); 2.03 times more likely than women with other types of insurance (CI 1.53-2.70).  There 
was no significant difference in the odds of being vaccinated between women with government 
insurance and those with charity care.  The odds of being vaccinated based on county of 
residence or ethnicity was not significant (Table 4).   
Table 4.  
Odds Ratios of Tdap Vaccination by Demographic Variables 
  
Odds 
Ratio Confidence Intervals 
Year 
2011 vs 2009 2.67 2.44-2.93* 
2011 vs 2010 1.55 1.42-1.69* 
Mother's Age 
 <20 vs 20-34 1.13 1.00-1.27* 
 <20 vs >or=35  1.21 1.03-1.42* 
County 
Outside Mont. County vs Mont. County 0.94 0.87-1.02 
Insurance 
Government vs Commercial 1.85 1.70-2.01* 
Government vs Self-Pay 1.69 1.08-2.63* 
Government vs Charity 0.82 0.62-1.09 
Government vs Other 2.03 1.53-2.70* 
Race 
Black vs White 1.11 1.01-1.22* 
Black vs Other 0.91 0.74-1.11 
Ethnicity 
Hispanic/Latino vs Not Hispanic/Latino 1.11 0.85-1.45 
Note. * signifies that the value is significant as p<0.05. 
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In regards to timing of immunization, 93% of vaccinated women received the Tdap 
vaccine in the immediate post-partum period.  Four percent of women were vaccinated with 
Tdap prior to conception.  Two percent of women received the vaccine during pregnancy, and 
1% received the vaccine in the 6-week post-partum period.  Broken down by year, the 
percentage of women vaccinated between 20 weeks gestation and birth increased by 41% over 
the study period, from 1.8% in 2009 to 2.5% in 2011.  In addition, the percentage of women 
vaccinated prior to gestation increased by 60%, from 3.5% in 2009 to 5.7% in 2011 (Figure 1). 
 
Figure 1. Timing of Tdap immunization by year of delivery using data collected from Miami 
Valley Hospital. 
 
Vaccination Rates, Influenza 
 From 2009-2011, 18% of women delivering at Miami Valley Hospital received an 
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in 2009 received the vaccine; 19% of women delivering in 2010; and, 23% of women delivering 
in 2011 received an influenza vaccine.  This 100% trend increase over the study period was 
statistically significant (p<0.0001).  During the H1N1 season, only 1.7% of women received both 
the seasonal influenza and H1N1 vaccines.  Other significant variables were county of residence, 
insurance status, race, and ethnicity.  Nineteen percent of women less than 20, 18% of women 
20-34 years old, and 16% of women 35 years or greater received the vaccine (p=0.6133).  Of 
women living in Montgomery County, 19% were vaccinated; 15% of women living outside 
Montgomery County received the vaccine (p<0.0001).  Sixteen percent of women with 
commercial insurance, 19% of women with government insurance, and 33.8% of women with 
charity care received FLUV (p<0.0001).  Regarding race, 17.4% of white women and 17.6% of 
black women received the vaccine, while 23% of women of other races received the vaccine 
(p=0.0194).  Twenty-seven percent of Hispanic/Latino women received the vaccine, while only 
17.5% of non-Hispanic/Latino women received the vaccine (p=0.0044) (Table 5).   
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Table 5.  
Analysis of Influenza Vaccination by Demographic Variables 
  Vaccinated n (%) Not vaccinated n (%) Chi-Square 
Year     <0.0001* 
2009 536 (11.33%) 4194 (88.67%) <0.0001* 
2010 857 (19.10%) 3631 (80.90%) <0.0001* 
2011 1050 (23.40%) 3437 (76.60%) - 
Mother's Age   0.6133 
<20  279 (18.78%) 1207 (81.22%) - 
20-34 1925 (17.92%) 8815 (82.08%) - 
>or=35 239 (16.17%) 1239 (83.93%) - 
County   <0.0001* 
Montgomery County 1643 (19.43%) 6814 (80.57%)     <0.0001* 
Outside Montgomery County 800 (15.25%) 4447 (84.75%) - 
Insurance   <0.0001* 
Commercial 900 (16.06%) 4705 (83.94%) 0.0011* 
Government 1426 (19.0%) 6080 (81.00%) - 
Self-Pay 9 (9.09%) 90 (90.91%) 0.0123* 
Charity 81 (33.75%) 159 (66.25%) 0.0002* 
Other 26 (10.28%) 227 (89.72%) 0.0009* 
Race   0.0194* 
White 1669 (17.39%) 7931 (82.61%) 0.0075* 
Black 545 (17.63%) 2546 (82.37%) - 
Other 226 (22.99%) 757 (77.01%) 0.0788 
Ethnicity   0.0044* 
Not Hispanic/Latino 2312 (17.51%) 10892 (82.49%) 0.0044* 
Hispanic/Latino 129 (27.04%) 348 (72.96%) - 
Note. * signifies that the value is significant as p<0.05. 
 
 The odds of receiving the vaccine were 1.27 times higher in 2011 than in 2010 (CI 1.15-
1.41) and 2.36 times higher in 2011 than 2009 (CI 2.10-2.64).  Women living within 
Montgomery County were 1.33 times more likely to receive FLUV than women living outside 
the county (CI 1.21-1.47).  Women with government insurance were 1.18 times more likely to be 
vaccinated than those with commercial insurance (CI 1.07-1.31); 2.41 times more likely than 
women self-paying (CI 1.22-4.83); 0.58 times as likely as women receiving charity care (CI 
0.44-0.77); and, 2.02 times more likely than women with other types of insurance (CI 1.22-3.06).  
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White women were 0.85 times as likely as black women to receive FLUV (CI 0.76-0.96); 
women of other races were 0.81 times as likely as black women to be vaccinated, although this 
was not statistically significant.  The odds of being vaccinated based on maternal age were not 
significant (Table 6).   
Table 6.  
Odds Ratios of Influenza Vaccination by Demographic Variables 
  
Odds 
Ratio Confidence Intervals 
Year 
2011 vs 2009 2.36 2.10-2.64* 
2011 vs 2010 1.27 1.15-1.41* 
Mother's Age 
 <20 vs 20-34 1.02 0.88-1.18 
 <20 vs >or=35  1.10 0.90-1.34 
County 
Mont. County vs. Outside Mont. County 1.33 1.21-1.47* 
Insurance 
Government vs Commercial 1.18 1.07-1.31* 
Government vs Self-Pay 2.41 1.22-4.83* 
Government vs Charity 0.58 0.44-0.77* 
Government vs Other 2.02 1.22-3.06* 
Race 
White vs Black 0.85 0.76-0.96* 
Other vs Black 0.81 0.63-1.03 
Ethnicity 
Hispanic/Latino vs Not Hispanic/Latino 1.55 1.15-2.09* 
Note. * signifies that the value is significant as p<0.05. 
 
 The timing of influenza vaccination varied from year to year.  In regards to timing of 
immunization, 3.5% of women received FLUV during the 1
st
 trimester, 15% of women received 
the vaccine in the 2
nd
 trimester, and 30.2% of women received the vaccine in the 3
rd
 trimester.  
Two percent of women were vaccinated during the influenza season just prior to conception, and 
48% of women were vaccinated in the postpartum period (from birth to six weeks of age).  There 
was a 67% increase over the study period in the percentage of women vaccinated in the 2nd 
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trimester, from 9% to 15%.  There was also a 35% increase in the percentage of women 
vaccinated in the postpartum period, from 39.8% to 53.8%.  In conjunction with these increased 
rates, there was a 45% decrease in the percentage of women vaccinated in the 3rd trimester, from 
45.4% to 25%.  Overall, 78% of women were vaccinated either in the 3rd trimester or in the 
postpartum period (Figure 2).   
 
Figure 2.  Timing of Influenza immunization by year of delivery using data collected from 
Miami Valley Hospital. 
 
Discussion 
Purpose of the Study with Research Questions 
This study examined the percentage of pregnant and postpartum women who received the 
pertussis and influenza vaccines as recommended.  A second objective of this study was to 
identify barriers to universal Tdap and FLUV immunization in unvaccinated women.  The results 
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vaccine during the study period, and 18% received FLUV.  Very few women received both 
seasonal and H1N1 influenza during the epidemic season, as recommended by the CDC.  The 
large majority of mothers who received Tdap were vaccinated in the immediate postpartum 
period, between birth and 10 days postpartum.  Women who received FLUV were most often 
vaccinated in the third trimester or immediate postpartum period, while very few women were 
vaccinated pre-conception or early in pregnancy.   
Women were less likely to receive the Tdap vaccine if they were older than 20 years, if 
they had commercial insurance or were self-pay, or if they were white.  Mothers were less likely 
to receive FLUV if they were living outside Montgomery County, if they had commercial 
insurance or were self-pay, if they were white, and if they were not Hispanic/Latino.  
Interestingly, age was not a significant variable for receipt of FLUV, while it was significant for 
Tdap.  In addition, county residence was a significant variable for receipt of FLUV, while it was 
not significant for receipt of Tdap.   
One of the main goals of Healthy People 2010 was to reduce health disparities, including 
disparities in vaccination coverage among population subgroups within the United States.  Using 
data from the National Immunization Survey, Zhao and Luman (2010) found that overall 
vaccination coverage increased from 2000 to 2008 and most disparities surrounding vaccination 
were reduced during this period.  However, as of 2008 significant disparities among some 
demographic factors still remain.  When adjusted for other factors, white children had 
significantly lower vaccination coverage compared to Hispanic children.  Also, children with 
more than one sibling were significantly less likely to be vaccinated compared to children with 
no siblings (Zhao & Luman, 2010).   
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While the data by Zhao and Luman (2010) does not directly analyze maternal 
demographic variables, white women may be less likely to be vaccinated across the US 
population, as was shown in the MVH study.  It is unclear why race would play a direct role in 
vaccine uptake.  It is possible that there are racial barriers in terms of access to vaccines.  In 
addition, racial disparities could be accounted for by provider bias.  Cultural factors may also 
play a role in vaccine uptake.  Interestingly, the MVH study showed that women with 
government insurance were more likely to receive both vaccines.  This may be because the 
immunizations were fully covered by insurance, while women with commercial insurance may 
have a co-payment (and women self-paying have to cover the entire cost).  However, insured 
mothers may be more likely to seek care in a private physician’s office, of which there were no 
records in this study.  Therefore, it is possible that insured mothers are just as likely, or even 
more likely, than women with government insurance to receive these vaccines.   
Other disparities have been shown to affect vaccination rates, and therefore incidence of 
disease.  In a recent study, Broutin, Viboud, Grenfell, Miller, and Rohani (2010) showed that 
periodicity in pertussis epidemics was a function of birth rate: the higher the birth rate, the 
shorter the periodicity.  Additionally, it is known that increased fertility is associated with 
poverty, high child mortality, low social status of women, and female illiteracy (Lindstrand et al., 
2006).  Children below the poverty line are less likely to be vaccinated, and mothers with <12 
years of education are less likely to vaccinate their children (Zhao & Luman, 2010).  While these 
disparities were studied in the context of childhood vaccination, they may also affect maternal 
vaccine uptake.   
For both Tdap and FLUV, the percentage of vaccine uptake increased each year, by 77% 
with Tdap and by 100% with FLUV.  This is in accordance with national trends.  As Tdap 
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vaccine safety is being studied in pregnant women, over time providers and patients should be 
more likely to utilize the vaccine.  In addition, as there is a national pertussis epidemic on-going 
in the United States, providers in all areas of health care are looking for ways to decrease the 
disease burden; therefore, they may be more likely to prescribe the vaccine to pregnant mothers 
in 2011 compared to 2009.  In terms of the influenza vaccine, rates increased tremendously, to 
nearly 50% of mothers vaccinated, during the H1N1 epidemic.  Rates also increased in this 
study, and 2011 data suggests that the trends are continuing.  This could be related to increased 
media exposure of the importance of the influenza vaccine, improved patient and provider 
education, and increased availability of the vaccine.   
Barriers to Vaccination 
Despite ACIP recommendations to vaccinate all postpartum women and close contacts 
against pertussis, some providers have been reluctant to adopt these standards, pushing the 
responsibility off to others in the medical field.  A 2006 study by Clark, Adolphe, Davis, Cowan, 
and Kretsinger found that only 78% of physicians would recommend Tdap for women during the 
postpartum stay even with national recommendations.  Barriers to implementation of vaccination 
in obstetrics-gynecology, with FLUV, Tdap, and others, include time constraints for counseling, 
lack of adequate knowledge regarding immunizations, financial burdens in maintaining stock of 
vaccines, and unknown immunization status of the woman (Clark, Adolphe, Davis, Cowan, & 
Kretsinger, 2006; Power et al., 2009; Ross et al., 2009; Tan, Bhattacharya, & Gerbie, 2011).  
Hospital records are often inadequate to provide immunization data, and many women do not 
know their immunization status.  In a study of primary care providers, only 53% of providers 
reported having vaccination records on greater than 50% their patients (Tan et al., 2011).  One 
study found that a majority (74%) of obstetricians felt that not knowing the date of the patient’s 
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last Td booster was a barrier to Tdap vaccination.  In the same study, 46% of obstetricians felt 
that patient resistance to vaccination was a barrier to receiving Tdap (Clark et al., 2006).  Not 
only do obstetricians identify barriers to influenza vaccination in pregnant mothers, but also 
other health care works such as nurses, medical assistants, receptionists and administrators are 
hesitant to encourage influenza vaccination.  In a 2009 study (Broughton, Beigi, Switzer, Raker, 
& Anderson), 31% of health care workers did not believe that vaccines were a safe and effective 
way to prevent disease; only 56.6% believed that pregnant women are at increased risk of disease 
from influenza infections; and, only 65% would recommend the influenza vaccine to pregnant 
mothers if indicated.    
Overall, lack of near-universal vaccination despite national recommendations can be 
explained by multiple barriers in both medical care and socioeconomics.  While specific barriers 
were not directly assessed in this research study, extrapolations from the data can be made as to 
why vaccination rates remain low.  To begin, it is likely that some obstetricians/gynecologists are 
not recommending the influenza and Tdap vaccines for numerous reasons (financial constraints, 
lack of knowledge, lack of self-efficacy, lack of time, etc).  In addition, as shown by Broughton 
et al. (2009), other health care providers are also wary of recommending vaccines during 
pregnancy.  Finally, mothers are wary of accepting vaccines during pregnancy, often due to 
concerns about safety and efficacy of the vaccine.  All of these barriers can be improved with 
better communication and education amongst healthcare providers and patients.    
Implications for Public Health Practice 
Social factors such as the failure to take up vaccination services even when available, 
ethnic and migrant status, and poorly trained health workers all affect vaccination uptake and 
influence whether mothers will be vaccinated (Zhao & Luman, 2010; Lindstrand et al., 2006).  
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These concepts contrast with the theory that vaccination is a “default” behavior, driven by 
demand and independent of social factors (Leach & Fairhead, 2007).  To increase uptake of 
vaccines, public health and medical providers must address these supply-side factors.  More 
emphasis is needed on education for patients, including the health illiterate and immigrant 
populations; on improving access for lower socioeconomic status patients; and, on improving 
training of healthcare workers.   
This data analysis at MVH shows that medical providers can do a better job to vaccinate 
mothers and other caregivers in order to protect infants.  Therefore, the next steps are to design 
an intervention that will target women- those who have already given birth, those who are 
pregnant, and those of childbearing age.  One way to target this group is through local public 
health campaigns.  These campaigns could include advertising at public events, radio or 
television ads, and other marketing strategies.  Other interventions should come from the medical 
side- obstetricians might create interventions such as educational brochures or develop one-on-
one educational sessions with trained healthcare workers to encourage women to accept the 
vaccines.  Primary care physicians should also improve education and awareness of the benefits 
of vaccination during pregnancy.  In addition, pediatricians can target mothers and other 
caregivers, both in clinics and in hospital settings, to get vaccinated.  Pediatricians can educate 
mothers that caring for their own health, which includes vaccination, can lead to a healthier life 
for their children.  Finally, standing protocols in birthing centers and even emergency 
departments may be an efficient intervention to increase vaccination rates, as has been shown in 
a hospital system in Chicago (Tan & Gerbie, 2010).   
Maternal vaccination within the MVH population is low, in terms of both influenza and 
Tdap vaccines.  However, as shown in the literature, other caregivers are often responsible for 
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 36 
disease transmission to infants (de Greeff et al., 2010; Jardine et al., 2010; Bisgard et al., 2004).  
While it is commendable that the CDC and ACOG encourage vaccination of mothers in order to 
protect infants, these and other medical bodies involved in public health should encourage 
fathers, grandparents, siblings, and other caregivers to be vaccinated, as they are often 
responsible for spreading the disease.  By fully cocooning the infant, disease transmission can be 
halted, leading to decreased infections, hospitalizations, and deaths.  In order to improve 
cocooning for influenza, more education is needed for parents and caregivers (Grizas, Camenga, 
& Vazquez, 2012).  In addition, for cocooning to be effective, immunization of all close contacts 
must take place at least four weeks prior to delivery so that a full immune response can occur.  
However, more research is needed in this area to determine if the strategy is efficient and cost-
effective. 
To address waning immunity as seen with both Tdap and FLUV, some proposed 
solutions are to create more antigenic vaccines, promote vaccination among patients and 
caregivers (FLUV and Tdap), and improve health infrastructure to eliminate access problems.  
One of the current challenges in controlling pertussis infections is the waning immunity that 
occurs with both natural infection and vaccination.  The newer Tdap vaccine should prevent 
waning immunity and disease transmission to susceptible populations by increasing the 
proportion of immune individuals, but it will only be successful if it is promoted by the medical 
and public health communities and accepted by patients.  Since access to health care is often a 
greater barrier for adults than for children, FLUV and Tdap immunization coverage of mothers 
and caregivers prior to pregnancy will likely be low until health infrastructure changes.  One 
innovative prevention tactic that could improve vaccination would be to implement standing 
order protocols at primary care centers.  These protocols would encourage vaccination of all 
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women of childbearing age with both FLUV and Tdap; they would also promote vaccination of 
fathers, grandparents, and other caregivers.  By encouraging vaccination of women before they 
become pregnant, one of the greatest barriers (concern over vaccine safety during pregnancy) can 
be circumvented. 
Limitations and Impact on Results 
 One of the greatest limitations of this analysis is that the dataset was incomplete.  While 
the dataset was large, a positive vaccination status was only identified if a woman received the 
vaccine within the Miami Valley Hospital system.  Therefore, if a woman were vaccinated 
within a different hospital system, at a private physician’s office, or at a local drugstore, the 
vaccination data would be missing from this dataset.  The rates of vaccination coverage in this 
study are an underrepresentation of the true percentage.  However, as the dataset was constant 
from year to year, the upward trends in vaccination for both FLUV and Tdap can be assumed to 
be generalizable to the local population.  A second limitation is that this analysis is a 
retrospective review, rather than a stronger prospective cohort study.  A third limitation is that 
there is no data for why a women did not receive a vaccine- whether it had not been offered, 
whether the woman had previously been vaccinated, or whether the woman declined for personal 
or religious reasons.  Therefore, analysis of the barriers to vaccination was limited.   
Conclusions 
Multiple medical organizations recommend vaccination with FLUV and Tdap for pregnant 
and postpartum mothers.  In the Miami Valley Hospital community, immunization with FLUV is less 
than 50%, and immunization with Tdap is approximately 50%.  In addition, vaccination with both 
FLUV and Tdap is occurring late, either in the third trimester for FLUV or the postpartum period for 
Tdap.  While receipt of the vaccine is important and applauded, disease prevention might be more 
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effective if the vaccines are given prior to pregnancy or earlier during pregnancy.  This may be 
achieved by improving education of healthcare providers (both physicians and other caregivers) and 
by improving patient education.  In addition, improved health infrastructure can make immunization 
more accessible and cost-effective, leading to increased vaccination rates.  Finally, the study shows 
that older women, white women, and women with commercial insurance or self-payment are less 
likely to receive vaccines during pregnancy or postpartum.  These populations should be targeted 
specifically in public health interventions to improve immunization rates.  Promisingly, trends from 
2009-2011 show that Tdap and FLUV vaccination rates are increasing.  Additional interventions by 
medical professionals, local public health districts, policymakers, and national campaigns may lead to 
improved vaccination rates, thereby decreasing morbidity and mortality for infants.     
  
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 39 
References 
Anderson, R., & May, R. M. (1990).  Immunisation and herd immunity.  Lancet, 335(8690), 641-646. 
Baxter, D. (2007).  Active and passive immunity, vaccine types, excipients and licensing.  
Occupational Medicine, 57(8), 552-526.   
Benowitz, I., Esposito, D. B., Gracey, K. D., Shapiro, E. D., & Vazquez, M. (2010).  Influenza 
vaccine given to pregnant women reduces hospitalizations due to influenza in their 
infants.  Clinical Infectious Diseases, 51(12), 1355-1361. 
Bisgard, K. M., Pascual, F. B., Ehresmann, K. R., Miller, C. A., Cianfrini, C., Jennings, C. E., . . 
. & Lett, S.M. (2004).  Infant pertussis: Who was the source?  The Pediatric Infectious 
Disease Journal, 23(11), 985-989.   
Bloom-Feshbach, K., Simonsen, L., Viboud, C., Mølbak, K., Miller, M. A., Gottfredsson, M., & 
Andreasen, V. (2011).  Natality decline and miscarriages associated with the 1918 
influenza pandemic: the Scandinavian and United States experiences.  Journal of 
Infectious Diseases, 204(18), 1157-1164.  
Blumental, S., Huisman, E., Cornet, M. C., Ferreiro, C., De Schutter, I., Reynders, M., . . . & 
Lepage, P. (2011).  Pandemic A/H1N1v influenza 2009 in hospitalized children: a 
multicenter Belgian survey.  BMC Infectious Diseases, 11(313). doi: 10.1186/1471-
2334-11-313 
Bouziri, A., Hamdi, A., Khaldi, A., Smaoui, H., Kechrid, A., Menif, K., & Ben Jaballah, N. 
(2010).  Malignant pertussis: An underdiagnosed illness.  [La coqueluche maligne: une 
maladie sous diagnostiquee] Medecine Tropicale: Revue Du Corps De Sante Colonial, 
70(3), 245-248.  
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 40 
Broughton, D. E., Beigi, R. H., Switzer, G. E., Raker, C. A., & Anderson, B. L. (2009).  
Obstetric health care workers’ attitudes and beliefs regarding influenza vaccination in 
pregnancy.  Obstetrics and Gynecology, 114(5), 981-987. 
Broutin, H., Viboud, C., Grenfell, B. T., Miller, M. A., & Rohani, P. (2010).  Impact of 
vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 
countries. Proceedings of the Royal Society, 277, 3239-3245.   
Castagnini, L. A., & Munoz, F. M. (2010).  Clinical characteristics and outcomes of neonatal 
pertussis: a comparative study. The Journal of Pediatrics, 156(3), 498-500. 
Castagnini, L. A., Healy, C. M., Rench, M. A., Wotton, S. H., Munoz, F. M., & Baker, C. J. 
(2012).  Impact of maternal postpartum tetanus and diphtheria toxoids and acellular 
pertussis immunization on infant pertussis infection. Clinical Infectious Diseases, 54(1), 
78-84. 
Centers for Disease Control and Prevention (CDC). (1999). Control of infectious diseases. 
Morbidity and Mortality Weekly Report, 48(29), 621-629. 
Centers for Disease Control and Prevention (CDC). (2008). Prevention of pertussis, tetanus, and 
diphtheria among pregnant and postpartum women and their infants: recommendations of 
the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly 
Report, 57, (No. RR-4).   
Centers for Disease Control and Prevention (CDC). (2010a). Notes from the field: Pertussis—
California, January—June 2010. Morbidity and Mortality Weekly Report, 59(26), 817. 
Centers for Disease Control and Prevention (CDC). (2010b). Pertussis (Whooping Cough).  
Retrieved on November 2, 2010, from http://www.cdc.gov/pertussis/index.html 
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 41 
Centers for Disease Control and Prevention (CDC). (2011a). Influenza vaccination coverage 
among pregnant women—United States, 2010—11 influenza season. Morbidity and 
Mortality Weekly Report, 60, 1078-1082. 
Centers for Disease Control and Prevention (CDC). (2011b). Maternal and infant outcomes 
among severely ill pregnant and postpartum women with 2009 pandemic influenza A 
(H1N1)—United States, April 2009-August 2010. Morbidity and Mortality Weekly 
Report, 60(35), 1193-1196.   
Centers for Disease Control and Prevention (CDC). (2011c). Seasonal influenza.  Retrieved on 
April 24, 2011, from http://www.cdc.gov/flu/about/qa/disease.htm 
Centers for Disease Control and Prevention (CDC). (2012a). Recommended adult immunization 
schedule—United States, 2012. Morbidity and Mortality Weekly Report, 61(4), 1-7.  
Centers for Disease Control and Prevention (CDC). (2012b). Recommended immunization 
schedules for persons aged 0 through 18 years—United States, 2012. Morbidity and 
Mortality Weekly Report, 61(05), 1-4. 
Clark, S. J., Adolphe, S., Davis, M. M., Cowan, A. E., & Kretsinger K. (2006). Attitudes of US 
obstetricians toward a combined tetanus-diphtheria-acellular pertussis vaccine for adults. 
Infectious Diseases in Obstetrics & Gynecology, 2006, 1-5. 
Cohen, S. A., Chui, K. K., & Naumova, E. N. (2011).  Influenza vaccination in young children 
reduced influenza-associated hospitalizations in older adults, 2002-2006.  Journal of the 
American Geriatrics Society, 59(2), 327-332.   
Coudeville, L, Van Rie, A., & Andre, P. (2008).  Adult pertussis vaccination strategies and their 
impact on pertussis in the United States: evaluation of routine and targeted (cocoon) 
strategies.  Epidemiology and Infection, 136(5), 604-620.   
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 42 
Dawood, F. S., Fiore, A., Kamimoto, L., Bramley, A., Reingold, A., Gershman, K., . . . & Finelli, 
L. (2010). Burden of seasonal influenza hospitalization in children, United States, 2003 to 
2008. Journal of Pediatrics, 157(5), 808-814.   
de Greeff, S. C., Mooi, F. R., Westerhof, A., Verbakel, J. M., Peeters, M. F., Heuvelman, C. J., . . 
. & de Melker, H. E. (2010). Pertussis disease burden in the household: How to protect 
young infants. Clinical Infectious Diseases, 50(10), 1339-1345. 
Fisher, B. M., Van Bockhern, J., Hart, J., Lynch, A. M., Winn, V. D., Gibbs, R. S., & Weinberg, 
A. (2012). Pandemic influenza A H1N1 2009 infection versus vaccination: a cohort study 
comparing immune responses in pregnancy. PLoS One, 7(3), e33048.   
Fortner, K. B., Kuller, J. A., Rhee, E. J., & Edwards, K. M. (2012). Influenza and tetanus, 
diphtheria, and acellular pertussis vaccines during pregnancy. Obstetrical and 
Gynecological Survey, 67(4), 251-257.  
Gall, S. A., Myers, J., & Pinchichero, M. (2011). Maternal immunization with tetanus-
diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. 
American Journal of Obstetrics and Gynecology, 204(4), 334.e1-5.  
Gerbie, M. V., & Tan, T. Q. (2009). Pertussis disease in new mothers: Effect on young infants 
and strategies for prevention. Obstetrics and Gynecology, 113(2 Pt 1), 399-401. 
Glezen, W.P. (2004). Control of influenza. Texas Heart Institute Journal, 31(1), 39-41. 
Grizas, A. P., Camenga, D., & Vazquez, M. (2012). Cocooning: A concept to protect young 
children from infectious disease. Current Opinion in Pediatrics, 24(1), 92-97. 
Healy, C., Rench, M. A., & Baker, C. J. (2011). Implementation of cocooning against pertussis 
in a high-risk population. Clinical Infectious Diseases, 52(2), 157-162. 
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 43 
Hobbs, J. R., & Davis, J. A. (1967). Serum gamma-G-globulin levels and gestational age in 
premature babies. Lancet, 1(7493), 757-759. 
Jardine, A., Conaty, S. J., Lowbridge, C., Staff, M., & Vally, H. (2010). Who gives pertussis to 
infants? source of infection for laboratory confirmed cases less than 12 months of age 
during an epidemic, Sydney, 2009. Communicable Diseases Intelligence, 34(2), 116-121. 
Jefferson, T., Smith, S., Demicheli, V., Harnden, A., Rivetti, A., & Di Pietrantonj, C. (2005a). 
Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: a 
systematic review. Lancet, 365(9461), 773-780. 
Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., & Demicheli, V. (2005b). 
Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. 
Lancet, 366(9492), 1165-1174.   
Kohler, P. F., & Farr, R. S. (1966). Elevation of cord over maternal IgG immunoglobulin: 
evidence for an active placental IgG transport. Nature, 210(5040), 1070-1071. 
Leach, M., & Fairhead, J. (2007). Vaccine Anxieties: Global science, child health and society. 
Earthscan: Virginia. 
Lindstrand, A., Bergstrom, S., Rosling, H., Rubenson, B., Stenson, B., & Tylleskar, T. (2006). 
Global Health: An introductory textbook. Studentlitteratur: Sweden. 
Loeb, M., Russell, M. L., Moss, L., Fonseca, K., Fox, J., Earn, D. J., . . . & Walter, S. D. (2010). 
Effect of influenza vaccination of children on infection rates in Hutterite communities: a 
randomized trial. Journal of the American Medical Association, 303(10), 943-950.   
Loeb, M., Russell, M. L., Fonseca, K., Webby, R., & Walter, S. D. (2011). Comparison of 
multiple estimates of efficacy for influenza vaccine. Vaccine 30(1), 1-4.   
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 44 
Louie, J. K., Acosta, M., Jamieson, D. J., Honein, M. A., & California Pandemic (H1N1) 
Working Group. (2010). Severe 2009 H1N1 influenza in pregnant and postpartum 
women in California. New England Journal of Medicine, 362(1), 27-35.  
Mouzoon, M. E., Munoz, F. M., Greisinger, A. J., Brehm, B. J., Wehmanen, O. A., Smith, F. A., 
. . . & Glezen, W. P. (2010). Improving influenza immunization in pregnant women and 
healthcare workers. American Journal of Managed Care, 16(3), 209-216.   
Murphy, T. V., Slade, B. A., Broder, K. R., Kretsinger, K., Tiwari, T., Joyce, P. M., . . . & 
Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and 
Prevention (CDC). (2008). Prevention of pertussis, tetanus, and diphtheria among 
pregnant and postpartum women and their infants of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recommendations & Reports, 57(RR-4), 1-51.  
Nicholson, K.G. (1992). Clinical features of influenza. Seminars in Respiratory Infections, 7(1), 
26-37. 
Pertussis vaccines: WHO Position Paper. (2010). WHO Weekly Epidemiologic Record, 85(40), 
385-400. 
Plans, P. (2010). Prevalence of antibodies associated with herd immunity: A new indicator to 
evaluate the establishment of herd immunity and to decide immunization strategies. 
Medical Decision Making, 30(4), 438-443. 
Plans-Rubio, P. (2012). The vaccination coverage required to establish herd immunity against 
influenza viruses. Preventive Medicine, 55(1), 72-77. 
Poehling, K. A., Szilagyi, P. G., Staat, M. A., Snively, B. M., Payne, D. C., Bridges, C. B., . . . & 
New Vaccine Surveillance Network. (2011). Impact of maternal immunization on 
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 45 
influenza hospitalization in infants. American Journal of Obstetrics and Gynecology, 
204(6), S141-148. 
Power, M. L., Leddy, M. A., Anderson, B. L., Gall, S. A., Gonik, B., & Schulkin, J. (2009). 
Obstetrician-Gynecologists’ practices and perceived knowledge regarding immunization. 
American Journal of Preventive Medicine, 37(3), 231-234. 
Quinello, C., Quintilio, W., Carneiro-Sampaio, M., & Palmeira, P. (2010). Passive acquisition of 
protective antibodies reactive with Bordetella pertussis in newborns via placental transfer 
and breast-feeding. Scandinavian Journal of Immunology, 72(1), 66-73. 
Rank, C., Quinn, H. E., & McIntyre, P. B. (2009). Pertussis vaccine effectiveness after mass 
immunization of high school students in Australia. Pediatric Infectious Disease Journal, 
28(2), 152-153.   
Reichert, T. A., Sugaya, N., Fedson, D. S., Glezen, W. P., Simonsen, L., & Tashiro, M. (2001). 
The Japanese experience with vaccinating schoolchildren against influenza. New England 
Journal of Medicine, 344(12), 889-896.   
Rimmelzwaan, G. F., Bodewes, R., & Osterhaus, A. D. (2011). Vaccination strategies to protect 
children against seasonal and pandemic influenza. Vaccine, 29(43), 7551-7553.   
Ross, D. S., Rasmussen, S. A., Cannon, M. J., Anderson, B., Kilker, K., Tumpey, A., . . . & 
Jones, J. L. (2009). Obstetrician/Gynecologists’ knowledge, attitudes, and practices 
regarding prevention of infections in pregnancy. Journal of Women’s Health, 18(8), 
1187-1193.   
Scuffham P. A., & McIntyre P. B. (2004). Pertussis vaccination strategies for neonates—an 
exploratory cost-effective analysis. Vaccine, 22, 3154-3165. 
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 46 
Skowronski, D. M., Janjua, N. Z., Tsafack, E. P., Ouakki, M., Hoang, L., & De Serres, G. 
(2012). The number needed to vaccinate to prevent infant pertussis hospitalization and 
death through parent cocoon immunization. Clinical Infectious Diseases, 54(3), 318-327. 
Steinhoff, M. C., Omer, S. B., Roy, E., Arifeen, S. E., Raqib, R., Dodd, C., . . . & Zaman, K. 
(2012). Neonatal outcomes after influenza immunization during pregnancy: a randomized 
controlled trial. Canadian Medical Association Journal, 184(6), 645-653.  
Tan, T. Q., & Gerbie, M.V. (2010). Pertussis and patient safety: Implementing Tdap vaccine 
recommendations in hospitals. The Joint Commission Journal on Quality and Patient 
Safety, 36(4), 173-178. 
Tan, T. Q., Bhattacharya, L., & Gerbie, M. V. (2011). Awareness, perceptions and knowledge of 
recommended adult vaccines among a nationwide sample of adult primary care providers.  
Journal of Reproductive Medicine, 56(7-8), 301-307. 
US Department of Health and Human Services. (2011). Immunization and infectious diseases. 
Healthy People 2020. Retrieved on April 24, 2012, from 
http://healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicId=23 
Van Rie, A., & Hethcote, H.W. (2004). Adolescent and adult pertussis vaccination: computer 
simulations of five new strategies. Vaccine, 22(23-24), 3154-3165.   
Ward, J. I., Cherry, J. D., Chang, S. J., Partridge, S., Lee, H., Treanor, J., . . . & Apert Study 
Group. (2005). Efficacy of an acellular pertussis vaccine among adolescents and adults.  
New England Journal of Medicine, 353(15), 1555-1563.   
Wei, S. C., Tatti, K., Cushing, K., Rosen, J., Brown, K., Cassiday, P., . . . & Martin, S. W. 
(2010). Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and 
acellular pertussis vaccine against pertussis. Clinical Infectious Diseases, 51(3), 315-321.  
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 47 
Wendelboe, A. M., Van Rie, A., Salmaso, S., & Englund, J. A. (2005). Duration of immunity 
against pertussis after natural infection or vaccination. Pediatric Infectious Disease 
Journal, 24(5 Suppl), S58-61.  
Wendelboe, A. M., Hudgens, M. G., Poole, C., & Van Rie, A. (2007a). Estimating the role of 
casual contact from the community in transmission of Bordetella pertussis to young 
infants. Emerging Themes in Epidemiology, 4, 15.  
Wendelboe, A. M., Njamkepo, E., Bourillon, A., Floret, D. D, Gaudelus, J., Gerber, M.,  . . . & 
Van Rie, A. (2007b). Transmission of Bordetella pertussis to young infants. Pediatric 
Infectious Disease Journal, 26(4), 293-299. 
Yen, C. J., Louie, J. K., & Schechter, R. (2012). Infants hospitalized in intensive care units with 
2009 H1N1 influenza infection, California, 2009-2010. Pediatric Infectious Disease 
Journal, 31(3), e52-55. 
Zhao, Z., & Luman, E. T. (2010). Progress toward eliminating disparities in vaccination 
coverage among U.S. children, 2000-2008. American Journal of Preventive Medicine, 
38(2), 127-137. 
  
VACCINATION OF PREGNANT AND POSTPARTUM WOMEN 48 
Appendices 
Appendix 1.  Tier 1 Core Public Health Competencies Met 
Domain #1: Analytic/Assessment 
Describe the characteristics of a population-based health problem (e.g., equity, social determinants, 
environment) 
Use variables that measure public health conditions 
Use methods and instruments for collecting valid and reliable quantitative and qualitative data 
Identify sources of public health data and information 
Recognize the integrity and comparability of data 
Identify gaps in data sources 
Adhere to ethical principles in the collection, maintenance, use, and dissemination of data and information 
Describe the public health applications of quantitative and qualitative data 
Collect quantitative and qualitative community data (e.g., risks and benefits to the community, health and 
resource needs) 
Use information technology to collect, store, and retrieve data 
Describe how data are used to address scientific, political, ethical, and social public health issues 
Domain #2: Policy Development and Program Planning 
Gather information relevant to specific public health policy issues 
Describe how policy options can influence public health programs 
Demonstrate the use of public health informatics practices and procedures (e.g., use of information systems 
infrastructure to improve health outcomes) 
Domain #3: Communication 
Participate in the development of demographic, statistical, programmatic and scientific presentations 
Domain #4: Cultural Competency 
Recognize the role of cultural, social, and behavioral factors in the accessibility, availability, acceptability and 
delivery of public health services 
Domain #5: Community Dimensions of Practice 
Recognize community linkages and relationships among multiple factors (or determinants) affecting health 
(e.g., The Socio-Ecological Model) 
Identify stakeholders 
Domain #6:Public Health Sciences 
Describe the scientific foundation of the field of public health 
Relate public health science skills to the Core Public Health Functions and Ten Essential Services of Public 
Health 
Identify the basic public health sciences (including, but not limited to biostatistics, epidemiology, environmental 
health sciences, health services administration, and social and behavioral health sciences) 
Describe the scientific evidence related to a public health issue, concern, or, intervention 
Retrieve scientific evidence from a variety of text and electronic sources 
Discuss the limitations of research findings (e.g., limitations of data sources, importance of observations and 
interrelationships) 
Describe the laws, regulations, policies and procedures for the ethical conduct of research (e.g., patient 
confidentiality, human subject processes) 
Domain #7: Financial Planning and Management – N/A 
Domain #8: Leadership and Systems Thinking 
Incorporate ethical standards of practice as the basis of all interactions with organizations, communities, and 
individuals 
Identify internal and external problems that may affect the delivery of Essential Public Health Services 
Use individual, team and organizational learning opportunities for personal and professional development 
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Appendix 2. Data Collection Tool 
Data Collection Instrument 
  A password protected Excel spreadsheet will be used to store the data.   
  The following parameters will be collected from each chart review: 
    
1 Medical Record Number (will be de-identified) 
2 Delivery Time and Date 
3 Mother Birth Date 
4 County of Residence 
5 Zip code 
6 Payer Status (Medicaid, private, military, etc.) 
7 Race 
8 Ethnicity 
9 Received Tdap immunization  
10 If received, date of immunization 
11 Received Influenza immunization  
12 If received, date of immunization 
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